HC Wainwright Brokers Lift Earnings Estimates for KPTI

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities researchers at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Karyopharm Therapeutics in a report issued on Wednesday, February 18th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($1.17) per share for the quarter, up from their prior forecast of ($1.56). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.79) EPS and FY2026 earnings at ($3.64) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million.

Several other equities research analysts have also recently issued reports on KPTI. Royal Bank Of Canada cut their target price on Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating for the company in a research note on Tuesday, November 4th. Piper Sandler reissued an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald initiated coverage on shares of Karyopharm Therapeutics in a research note on Thursday, February 5th. They set an “overweight” rating for the company. Finally, Wall Street Zen upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 8th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.83.

Karyopharm Therapeutics Stock Performance

KPTI stock opened at $9.67 on Friday. Karyopharm Therapeutics has a one year low of $3.51 and a one year high of $10.38. The firm has a market cap of $177.35 million, a PE ratio of -0.58 and a beta of 0.21. The firm’s 50 day moving average price is $7.21 and its 200-day moving average price is $6.38.

Institutional Investors Weigh In On Karyopharm Therapeutics

Large investors have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. boosted its position in Karyopharm Therapeutics by 112.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock valued at $10,977,000 after buying an additional 790,417 shares during the period. Ikarian Capital LLC grew its stake in Karyopharm Therapeutics by 1,897.9% during the 4th quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after purchasing an additional 517,297 shares in the last quarter. Geode Capital Management LLC raised its position in Karyopharm Therapeutics by 101.2% in the 4th quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock valued at $1,382,000 after purchasing an additional 94,445 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Karyopharm Therapeutics by 26.8% in the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares during the period. Finally, Boothbay Fund Management LLC acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter worth about $1,064,000. 66.44% of the stock is owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.